Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Adults at Risk for Heart Failure
NCT06507657Phase 1Recruiting
- Sponsor
- University of Minnesota
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empagliflozin in heart failure (HF) (2 arms), sponsored by University of Minnesota. Primary endpoint: Change in left atrial function at 9 months. Started Dec 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06507657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507657.